Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery

Anty, Rodolphe; Marjoux, Sophie; Iannelli, Antonio; Patouraux, Stéphanie; Schneck, Anne-Sophie; Bonnafous, Stéphanie; Gire, C.; Amzolini, Anca Maria; Ben-Amor, Imed; Saint–Paul, Marie–Christine; Mariné-Barjoan, Eugènia; Pariente, Alexandre; Gugenheim, Jean; Gual, Philippe; Tran, Albert

doi:10.1016/j.jhep.2012.07.014

Cited by 128 publications

(133 citation statements)

References 31 publications

Supporting

Mentioning

130

Contrasting

Order By: Relevance

“…Study (first author and year) Total caffeine intake (mg/day) Birerdinc et al [2012] Total caffeine intake (mg/day) Catalano et al [2010] Espresso coffee intake (cups/day) Gutierrez-Grobe et al [2012] Total caffeine intake (mg/day) Bambha et al [2014] Coffee (unspecified) intake (cups/day) Anty et al [2012] Total caffeine intake (g/week), caffeine from espresso, regular coffee, tea and chocolate or soda (g/week) Molloy et al [2012] Total caffeine or regular coffee caffeine intake (mg/day) significant benefit remains unclear, it is clear that the potential benefit of coffee needs to be further investigated.…”

Section: Discussionmentioning

confidence: 99%

Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis

Shen

Rodriguez

Shiani

et al. 2015

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Objectives: Caffeine consumption is reported to be associated with reduced hepatic fibrosis in patients with chronic liver diseases. We performed a systematic review and meta-analysis to assess the association between caffeine consumption and prevalence or hepatic fibrosis of nonalcoholic fatty liver disease (NAFLD) in observational studies. Methods:We searched the literature of all languages from PubMed, EMBASE, and the Cochrane library from 1 January 1980 through 10 January 2015. Total caffeine consumption was defined as the daily intake of caffeine (mg/day) from all caffeine-containing products. Combined and subgroup analyses stratified by study designs, study locations, and type of caffeine intake were performed. Results: Four cross-sectional and two case control studies with a total of 20,064 subjects were included in the meta-analysis. Among these, three studies with 18,990 subjects were included in the analysis for prevalence of NAFLD while the other three studies with 1074 subjects were for hepatic fibrosis. Total caffeine consumption (mg/day) was not significantly associated with either the prevalence [pooled mean difference (MD) 2.36; 95% confidence interval (CI) −35.92 to 40.64] or hepatic fibrosis (higher versus lower stages; pooled MD −39.95; 95% CI −132.72 to 52.82) of NAFLD. Subgroup analyses stratified by study designs and locations were also not significant. However, after stratifying by type of caffeine intake, regular coffee caffeine intake (mg/day) was significantly associated with reduced hepatic fibrosis of NAFLD (pooled MD −91.35; 95% CI −139.42 to −43.27; n = 2 studies). Conclusion: Although total caffeine intake is not associated with the prevalence or hepatic fibrosis of NAFLD, regular coffee caffeine consumption may significantly reduce hepatic fibrosis in patients with NAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis

Shen

Rodriguez

Shiani

et al. 2015

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…In another case control study from Mexico 130 subjects participated in a study investigating the potential antioxidant effect of coffee showed a dose-dependent reduction in caffeine intake with increasing severity of steatosis (diagnosed by ultrasonography), although no significant difference in antioxidant enzymes and lipid peroxidation markers was found [15]. Furthermore, a French study in 195 bariatric patients with biopsy-proven NAFLD showed that the consumption of regular coffee was an independent protective factor for liver fibrosis [9]. In addition, 782 adults from the Nonalcoholic Steatohepatitis Clinical Research.…”

Section: Coffee and Nafld/nashmentioning

confidence: 98%

“…In addition, coffee has been found to reduce fibrosis in animal tissue by decreasing the expression of growth factor-b, which is responsible for the connective tissue growth factor that contributes to increase accumulation of fat in hepatic cells [7]. Furthermore, many studies have suggested the caffeine consumption plays a protective role in NAFLD [8][9][10].…”

Section: Mechanism Of Action and Dose Safetymentioning

confidence: 99%

A Mini Updated Review on the Role of Coffee in Non-Alcoholic Fatty Liver Disease

Papandreou

2017

JLRDT

View full text Add to dashboard Cite

show abstract

“…Coffee consumption is associated with an overall decrease in mortality of 12 % when compared no coffee consumption [78]. The benefit of filtered coffee cannot be reproduced in espresso nor tea [79]. Daily caffeine intake above two cups of coffee is associated with lower rate of hepatic fibrosis [80] including in patients with NASH [81].…”

Section: Non-pharmacological Therapymentioning

confidence: 99%

An Update of Liver Transplantation for Nonalcoholic Steatohepatitis

Thomason

Charlton

2015

Curr Hepatology Rep

View full text Add to dashboard Cite

Nonalcoholic steatohepatitis (NASH), obesity, and the metabolic syndrome are highly prevalent before and after liver transplantation, with NASH currently the second most common indication. This review considers established and new aspects of liver transplantation for NASH. NASH is one of many sequelae of obesity and most frequently occurs on a background of the metabolic syndrome. While recurrence of steatosis is common, recurrence of NASH with advanced stages of fibrosis is unusual, with graft loss due to recurrence of NASH cirrhosis occurring with a frequency of less than 5 %. In contrast, the components of the metabolic syndrome, which are important predictors of posttransplant outcomes, are nearly ubiquitous following liver transplantation and are exacerbated by factors such as immunosuppression. As many aspects of the metabolic syndrome are modifiable, screening for and treating complications of obesity and minimization of immunosuppression are cornerstones of optimizing outcomes for transplant recipients with NASH. The optimal approach to immunosuppression, the role of bariatric surgery, and nutritional and pharmacotherapy of NASH in liver transplant recipients are evolving rapidly. Overall, a minimalist approach to immunosuppression is advised.

show abstract

Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery

Cited by 128 publications

References 31 publications

Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis

Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis

A Mini Updated Review on the Role of Coffee in Non-Alcoholic Fatty Liver Disease

An Update of Liver Transplantation for Nonalcoholic Steatohepatitis

Contact Info

Product

Resources

About